Cerebrolysin has no FDA-approved label, so every figure here traces back to clinical trials rather than a prescribing guideline. It is a clinical product given by healthcare professionals as intravenous infusions or intramuscular injections in defined courses, not a self-administered protocol.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026Cerebrolysin is a clinical product given by healthcare professionals in countries where it is approved, not a self-administered protocol. The figures below describe what trials used, given as intravenous infusions or intramuscular injections in defined courses:
Across studied settings, trials used roughly 10 to 50 mL per day. Acute ischaemic stroke trials commonly used up to 30 mL/day intravenously for about 10 days; the CAPTAIN I traumatic brain injury trial used 50 mL/day for 10 days followed by two cycles of 10 mL/day for 10 days. Treat these as a description of what was studied, verified against the primary source, not a recommendation.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.